Logo image of UROY

URANIUM ROYALTY CORP (UROY) Stock Fundamental Analysis

NASDAQ:UROY - Nasdaq - CA91702V1013 - Common Stock - Currency: USD

1.9024  -0.03 (-1.43%)

Fundamental Rating

2

Taking everything into account, UROY scores 2 out of 10 in our fundamental rating. UROY was compared to 213 industry peers in the Oil, Gas & Consumable Fuels industry. While UROY seems to be doing ok healthwise, there are quite some concerns on its profitability. UROY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

UROY had negative earnings in the past year.
In the past year UROY has reported a negative cash flow from operations.
In the past 5 years UROY reported 4 times negative net income.
In the past 5 years UROY always reported negative operating cash flow.
UROY Yearly Net Income VS EBIT VS OCF VS FCFUROY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

UROY has a worse Return On Assets (0.36%) than 67.61% of its industry peers.
UROY has a worse Return On Equity (0.36%) than 67.61% of its industry peers.
Industry RankSector Rank
ROA 0.36%
ROE 0.36%
ROIC N/A
ROA(3y)-0.67%
ROA(5y)-1.53%
ROE(3y)-0.79%
ROE(5y)-1.61%
ROIC(3y)N/A
ROIC(5y)N/A
UROY Yearly ROA, ROE, ROICUROY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -5 -10 -15

1.3 Margins

UROY has a Profit Margin of 4.65%. This is comparable to the rest of the industry: UROY outperforms 40.85% of its industry peers.
UROY's Gross Margin of 63.78% is fine compared to the rest of the industry. UROY outperforms 69.48% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 4.65%
GM 63.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UROY Yearly Profit, Operating, Gross MarginsUROY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

More info and screens

6

2. Health

2.1 Basic Checks

UROY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, UROY has more shares outstanding
UROY has more shares outstanding than it did 5 years ago.
The debt/assets ratio for UROY has been reduced compared to a year ago.
UROY Yearly Shares OutstandingUROY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
UROY Yearly Total Debt VS Total AssetsUROY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

UROY has an Altman-Z score of 168.63. This indicates that UROY is financially healthy and has little risk of bankruptcy at the moment.
UROY's Altman-Z score of 168.63 is amongst the best of the industry. UROY outperforms 99.53% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that UROY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, UROY belongs to the top of the industry, outperforming 84.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 168.63
ROIC/WACCN/A
WACC9.12%
UROY Yearly LT Debt VS Equity VS FCFUROY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

UROY has a Current Ratio of 216.58. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
UROY has a Current ratio of 216.58. This is amongst the best in the industry. UROY outperforms 100.00% of its industry peers.
UROY has a Quick Ratio of 16.29. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 16.29, UROY belongs to the top of the industry, outperforming 97.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 216.58
Quick Ratio 16.29
UROY Yearly Current Assets VS Current LiabilitesUROY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

UROY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -89.20%.
Looking at the last year, UROY shows a very negative growth in Revenue. The Revenue has decreased by -47.81% in the last year.
EPS 1Y (TTM)-89.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-148.67%
Revenue 1Y (TTM)-47.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.97%

3.2 Future

The Earnings Per Share is expected to decrease by -32.80% on average over the next years. This is quite bad
The Revenue is expected to decrease by -2.88% on average over the next years.
EPS Next Y-90.47%
EPS Next 2Y-49.6%
EPS Next 3Y-17.02%
EPS Next 5Y-32.8%
Revenue Next Year-50.31%
Revenue Next 2Y-36.86%
Revenue Next 3Y-39.63%
Revenue Next 5Y-2.88%

3.3 Evolution

UROY Yearly Revenue VS EstimatesUROY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M
UROY Yearly EPS VS EstimatesUROY Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

UROY is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UROY Price Earnings VS Forward Price EarningsUROY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UROY Per share dataUROY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

UROY's earnings are expected to decrease with -17.02% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-49.6%
EPS Next 3Y-17.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UROY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

URANIUM ROYALTY CORP

NASDAQ:UROY (5/7/2025, 10:45:03 AM)

1.9024

-0.03 (-1.43%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)03-06 2025-03-06
Earnings (Next)09-10 2025-09-10
Inst Owners25.1%
Inst Owner Change9.82%
Ins Owners2.18%
Ins Owner ChangeN/A
Market Cap254.24M
Analysts77.5
Price Target3.46 (81.88%)
Short Float %13.21%
Short Ratio5.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-49.5%
Min EPS beat(2)-100%
Max EPS beat(2)0.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-51.79%
Min Revenue beat(2)-99.97%
Max Revenue beat(2)-3.62%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.22%
PT rev (3m)-31.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-133.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-33.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-9.61%
Revenue NY rev (3m)-38.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.17
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.13
BVpS1.61
TBVpS1.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.36%
ROE 0.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 4.65%
GM 63.78%
FCFM N/A
ROA(3y)-0.67%
ROA(5y)-1.53%
ROE(3y)-0.79%
ROE(5y)-1.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 216.58
Quick Ratio 16.29
Altman-Z 168.63
F-Score3
WACC9.12%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-89.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-148.67%
EPS Next Y-90.47%
EPS Next 2Y-49.6%
EPS Next 3Y-17.02%
EPS Next 5Y-32.8%
Revenue 1Y (TTM)-47.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.97%
Revenue Next Year-50.31%
Revenue Next 2Y-36.86%
Revenue Next 3Y-39.63%
Revenue Next 5Y-2.88%
EBIT growth 1Y-114.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-179.8%
EBIT Next 3Y-91.12%
EBIT Next 5Y-42.34%
FCF growth 1Y-154.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.38%
OCF growth 3YN/A
OCF growth 5YN/A